Key Highlights
- Elucid appoints Kelly Huang, PhD, as new CEO.
- Huang brings extensive market planning and commercialization expertise.
- Elucid prepares for commercial launch of PlaqueIQ software.
- Recent $80 million Series C funding to support expansion.
Source: Business Wire
Notable Quotes
- “Kelly brings a history of successful commercialization and growth experience to Elucid at a critical time in the company’s progression to commercial operations.” — Scott Huennekens, Executive Chairman of Board of Directors at Elucid
- “I am energized to lead Elucid at such an exciting and important time, and I’m eager to help maximize the impact of its AI technology to improve patient care and make a positive impact in the field of cardiovascular disease management.” — Kelly Huang, PhD, CEO at Elucid
SoHC's Take
The appointment of Kelly Huang, PhD, as CEO marks a significant milestone for Elucid as it transitions towards the commercial launch of its groundbreaking PlaqueIQ software. Huang’s extensive background in market planning and commercialization will be invaluable in navigating the complexities of launching a medical technology product. His leadership is expected to accelerate Elucid’s growth and solidify its position in the cardiovascular imaging market. The recent $80 million Series C funding further underscores investor confidence in Elucid’s innovative approach to cardiovascular disease management.
